Nectin & Merck to Study Novel Anti-PVR Cancer Drug Candidate with Keytruda
Nectin Therapeutics Ltd. (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments, announced today that it has entered into a clinical trial collaboration…
Continue Reading
Nectin & Merck to Study Novel Anti-PVR Cancer Drug Candidate with Keytruda